Wolf-Hirschhorn syndrome candidate 2 protein (NELFA) (WHSC2)

Wolf-Hirschhorn syndrome candidate 2 protein (WHSC2), also known as NELFA, is a core component of the Negative Elongation Factor (NELF) complex, which is essential for regulating gene expression in eukaryotes (UniProt Q9H3P2). The NELF complex mediates the pausing of RNA polymerase II (Pol II) at the promoter-proximal region of genes, a critical checkpoint that controls the transition to productive elongation (PubMed PMID: 12612062). This mechanism allows for the rapid and synchronized induction of genes in response to developmental or environmental signals (PubMed PMID: 23435261). WHSC2 specifically interacts with the Pol II machinery and other NELF subunits to stabilize the paused state, thereby modulating the rate of transcription (NCBI Gene: 7469). In clinical contexts, WHSC2 is primarily recognized for its role in Wolf-Hirschhorn syndrome (WHS), a contiguous gene deletion syndrome involving the 4p16.3 chromosomal region (PubMed PMID: 10077617). The loss of WHSC2 contributes to the developmental delays, growth retardation, and craniofacial features characteristic of the disorder (PubMed PMID: 25838448). Beyond developmental biology, WHSC2 has emerged as a potential therapeutic target in oncology, as its dysregulation is linked to the progression of various cancers, and it has been identified as a target for tumor-specific cytotoxic T lymphocytes (PubMed PMID: 11230495). While no small-molecule inhibitors specifically targeting WHSC2 are currently in clinical use, the protein's role in transcriptional control and its involvement in cardiac development make it a focal point for research into transcription-targeted therapies.

Other names

NELFANELF-AP/OKcl.15Negative elongation factor complex member A

Regulation of RNA polymerase II pausing and elongation through the stabilization of the NELF complex at the promoter-proximal region.